Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Mark G. Kris, Paul J. Hesketh, Mark R. Somerfield et al. · Journal of Clinical Oncology · 2006 · 743 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Richard J. Gralla, M. Lichinitser, S. van der Vegt et al. · Annals of Oncology · 2003 · 471 citations

Medicine, Oncology, Pharmacology +17

Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist

Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer · 2003 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Matti Aapro, Steven M. Grunberg, George Manikhas et al. · Annals of Oncology · 2006 · 340 citations · Full text

Medicine, Oncology, Pharmacology +16

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

Annals of Oncology · 2005 · 327 citations · Full text

Medicine, Oncology, Radiation Oncology +14